- UCB (UCBJY, Financial) and Domino Data Lab have embarked on a strategic collaboration to modernize the Statistical Computing Environment (SCE) for life sciences.
- The initiative focuses on creating a cloud-enabled platform that integrates analytical tools like SAS, R, and Python while adhering to regulatory standards.
- This collaboration aims to accelerate drug development and enhance clinical research through advanced data analysis capabilities.
UCB (UCBJY), a prominent biopharmaceutical company, has joined forces with Domino Data Lab to modernize their Statistical Computing Environment (SCE) in the life sciences sector. This strategic collaboration aims to transform the legacy computing environment into a unified cloud-based platform. The platform will integrate powerful analytical tools including SAS, R, and Python within a scalable and flexible infrastructure.
The partnership emphasizes regulatory compliance with GxP, FDA 21 CFR Part 11, and GDPR, ensuring that the new SCE adheres to industry standards. By leveraging Domino's expertise in cloud technologies and UCB's clinical research knowledge, the collaboration aims to enhance research capabilities significantly.
This modernized SCE is expected to accelerate drug development processes, providing streamlined access to state-of-the-art analytical tools. This should enable more efficient clinical studies, allowing for faster therapy development and offering innovative treatment options for patients facing severe diseases.
According to Mike Branson, Senior Vice President at UCB, the collaboration is part of UCB's broader strategy to leverage pathways, populations, and technology platforms to deepen the understanding of disease biological causes. Meanwhile, Nick Elprin, CEO of Domino Data Lab, highlights the shared commitment to driving life sciences innovation, emphasizing the potential to challenge industry norms and establish global standards for statistical environments.
